Rainer Strotmann
5PUBLICATIONS
28CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher
|Aug 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann
|Jul 18, 2025
Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P-Gp: Drug Interaction Studies and Physiologically-Based Pharmacokinetic Analysis.Rainer Strotmann, Christian Lüpfert, Axel Krebs-Brown
|Oct 24, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.Hong Lu, Lena Klopp-Schulze, Jatinder Kaur Mukker
|Jun 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg
Pageof 1
Frequent Collaborators
4 joint publications
Karthik Venkatakrishnan
3 joint publications
Wei Gao
2 joint publications
Timothy A Yap
2 joint publications
Jatinder Kaur Mukker
2 joint publications
Paul Matthias Diderichsen
2 joint publications
Ioannis Gounaris
2 joint publications
Axel Krebs-Brown
1 joint publications
Zoltan Szucs
1 joint publications
Hong Lu
1 joint publications
Dandan Li
